drugset / Trial / NCT01101139

Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery

NCT01101139 ↗

Phase 4 Completed 300 enrolled Technical University of Munich
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to investigate, whether Sugammadex improves muscle function after standard neuromuscular recovery (TOF 0.9) from relaxation with rocuronium.

Timeline

Start
2010-04
Primary completion
2011-05
Completion
2011-06

Outcome

Missed primary endpoint

paper Antagonizing rocuronium at TOF≥0.9 with sugammadex 1.0 mg kg(-) (1) did not improve patients' motor function or well-being when compared with placebo. PMID 25586724 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sugammadex Other / unclassified 0.25 mg/kg Intravenous

Indications

No indication recorded.